MicroRNAs targeting EGFR signalling pathway in colorectal cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 10, 2013, Pages 1615-1624

  Mlcochova, Jitka ^a,b   Faltejskova, Petra ^a,b   Nemecek, Radim ^b   Svoboda, Marek ^a,b   Slaby, Ondrej ^a,b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Colorectal cancer; EGFR signalling pathway; MicroRNA; Predictive biomarkers; Prognostic biomarkers

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PANITUMUMAB; PROTEIN KINASE B BETA; STAT1 PROTEIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PEA3; TUMOR MARKER; UNCLASSIFIED DRUG;

AKT2 GENE; BRAF GENE; COLORECTAL CANCER; DISEASE MARKER; DRUG TARGETING; ERK1 GENE; ERK2 GENE; ERK5 GENE; FLI GENE; FOXO1 GENE; FOXO4 GENE; GENE EXPRESSION REGULATION; HUMAN; KRAS GENE; MEK2 GENE; METASTASIS; MTOR GENE; NF KAPPA B GENE; ONCOGENE; ONCOGENE C MYC; PDCD4 GENE; PIK3CA GENE; PIK3CB GENE; PIK3CD GENE; PREDICTION; PRIORITY JOURNAL; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; STAT1 GENE; TCF GENE;

COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84884670666     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1470-9     Document Type: Review

References (70)

1. Akao Y, Nakagawa Y, Naoe T (2006) MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16:845-850
2. Allgayer H (2010) Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol 73:185-191. doi: 10.1016/j.critrevonc.2009.09. 001
3. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634. doi: 10.1200/JCO.2007.14.7116
4. Arcaroli JJ, Quackenbush KS, Powell RW et al (2012) Common PIK3CA mutants and a novel 3′ UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 18:2704-2714. doi: 10.1158/1078-0432.CCR-11-3167
5. Bakirtzi K, Hatziapostolou M, Karagiannides I et al (2011) Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 141(1749-1761):e1. doi: 10.1053/j.gastro.2011.07.038
6. Barault L, Veyrie N, Jooste V et al (2008) Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255-2259. doi: 10.1002/ijc.23388
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643-2648. doi: 10.1158/0008-5472.CAN-06-4158
8. Borralho PM, Kren BT, Castro RE et al (2009) MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 276:6689-6700. doi: 10.1111/j.1742-4658.2009.07383.x
9. Chen X, Guo X, Zhang H et al (2009) Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28:1385-1392. doi: 10.1038/onc.2008.474
10. Chiang Y, Song Y, Wang Z et al (2011) Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg 15:63-70. doi: 10.1007/s11605-010-1367-8
11. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174. doi: 10.1056/NEJMra0707704
12. De Roock W, De Vriendt V, Normanno N et al (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594-603. doi: 10.1016/S1470-2045(10)70209-6
13. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712. doi: 10.1200/JCO.2008.18.0786
14. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS et al (2009) MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 101:707-714. doi: 10.1038/sj.bjc.6605037
15. Dobashi Y, Watanabe Y, Miwa C et al (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4:476-495
16. Earle JSL, Luthra R, Romans A et al (2010) Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 12:433-440. doi: 10.2353/jmoldx.2010.090154
17. Ferlay J, Shin H-R, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
18. Gao J-S, Zhang Y, Tang X et al (2011) The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett 585:693-699. doi: 10.1016/j.febslet.2011.01.033
19. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410-7425. doi: 10.1038/sj.onc.1209086
20. Gregersen LH, Jacobsen AB, Frankel LB et al (2010) MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS ONE 5:e8836. doi: 10.1371/journal. pone.0008836
21. Guo C, Sah JF, Beard L et al (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47:939-946. doi: 10.1002/gcc.20596
22. Humphreys KJ, Cobiac L, Le Leu RK et al (2013) Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog 52:459-474. doi: 10.1002/mc.21879
23. Iwaya T, Yokobori T, Nishida N et al (2012) Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis 33:2391-2397. doi: 10.1093/carcin/bgs288
24. Jahid S, Sun J, Edwards RA et al (2012) miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2:540-553. doi: 10.1158/2159-8290.CD-11-0267
25. Kent OA, Fox-Talbot K, Halushka MK (2012) RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene. doi: 10.1038/onc.2012.266
26. Kern HB, Niemeyer BF, Parrish JK et al (2012) Control of MicroRNA-21 expression in colorectal cancer cells by oncogenic epidermal growth factor/Ras signaling and Ets transcription factors. DNA Cell Biol 31:1403-1411. doi: 10.1089/dna.2011.1469
27. Kim HS, Lee M-S (2007) STAT1 as a key modulator of cell death. Cell Signal 19:454-465. doi: 10.1016/j.cellsig.2006.09.003
28. Kim NH, Kim HS, Kim N-G, et al. (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 4:ra71. doi: 10.1126/scisignal.2001744
29. Langlois M-J, Bergeron S, Bernatchez G et al (2010) The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS ONE 5:e15742. doi: 10.1371/journal.pone. 0015742
30. Li J, Chen Y, Zhao J et al (2011a) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304:52-59. doi: 10.1016/j.canlet.2011.02.003
31. Li J, Zhang Y, Zhao J et al (2011b) Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem 357:31-38. doi: 10.1007/s11010-011-0872-8
32. Liu X, Zhang Z, Sun L et al (2011) MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 32:1798-1805. doi: 10.1093/carcin/bgr213
33. Lu Z, Liu M, Stribinskis V et al (2008) MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27:4373-4379. doi: 10.1038/onc.2008.72
34. Motoyama K, Inoue H, Takatsuno Y et al (2009) Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34:1069-1075
35. Nakajima G, Hayashi K, Xi Y et al (2006) Non-coding MicroRNAs hsa-let-7 g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 3:317-324
36. Nishida N, Yokobori T, Mimori K et al (2011) MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 38:1437-1443. doi: 10.3892/ijo.2011.969
37. Nishimura J, Handa R, Yamamoto H et al (2012) microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep 28:2221-2226. doi: 10.3892/or.2012.2059
38. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. doi: 10.1038/msb4100014
39. Oikawa T, Yamada T (2003) Molecular biology of the Ets family of transcription factors. Gene 303:11-34
40. Ota T, Doi K, Fujimoto T et al (2012) KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 32:2271-2275
41. Pagliuca A, Valvo C, Fabrizi E et al (2012) Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. doi: 10.1038/onc.2012.495
42. Pekow JR, Dougherty U, Mustafi R et al (2012) miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis 18:94-100. doi: 10.1002/ibd.21742
43. Pichler M, Winter E, Stotz M et al (2012) Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer 106:1826-1832. doi: 10.1038/bjc.2012.175
44. Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116-129. doi: 10.1136/gut.2009.206250
45. Pu X, Huang G, Guo H et al (2010) Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 25:1674-1680. doi: 10.1111/j.1440-1746.2010.06417.x
46. Roskoski R Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66:105-143. doi: 10.1016/j.phrs.2012.04.005
47. Rossi L, Bonmassar E, Faraoni I (2007) Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56:248-253. doi: 10.1016/j.phrs.2007.07. 001
48. Roy HK, Olusola BF, Clemens DL et al (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23:201-205
49. Sachdeva M, Zhu S, Wu F et al (2009) p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106:3207-3212. doi: 10.1073/pnas.0808042106
50. Schetter AJ, Leung SY, Sohn JJ et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436. doi: 10.1001/jama.299.4.425
51. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308. doi: 10.1038/nrc2109
52. Sebio A, Paré L, Páez D et al (2013) The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet Genomics 23:142-147. doi: 10.1097/FPC. 0b013e32835d9b0b
53. Smits KM, Paranjape T, Nallur S et al (2011) A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723-7731. doi: 10.1158/1078-0432.CCR-11-0990
54. Sood A, McClain D, Maitra R et al (2012) PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 11:143-150. doi: 10.1016/j.clcc.2011.12.001
55. Sureban SM, May R, Ramalingam S, et al (2009) Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. Gastroenterology 137:649-659, 659.e1-659.e2. doi: 10.1053/j.gastro.2009.05.004
56. Tsang WP, Kwok TT (2009) The miR-18a*microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis 30:953-959. doi: 10.1093/carcin/bgp094
57. Vecchione L, Jacobs B, Normanno N et al (2011) EGFR-targeted therapy. Exp Cell Res 317:2765-2771. doi: 10.1016/j.yexcr.2011.08.021
58. Vickers MM, Bar J, Gorn-Hondermann I et al (2012) Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 29:123-132. doi: 10.1007/s10585-011-9435-3
59. Wienholds E, Plasterk RHA (2005) MicroRNA function in animal development. FEBS Lett 579:5911-5922. doi: 10.1016/j.febslet.2005.07.070
60. Wu J, Qian J, Li C et al (2010) miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle Georget Tex 9:1809-1818
61. Wu L, Li H, Jia CY et al (2012) MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett 586:1038-1043. doi: 10.1016/j.febslet.2012.02. 050
62. Wu W, Yang J, Feng X et al (2013) MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 12:30. doi: 10.1186/1476-4598-12-30
63. Xi Y, Formentini A, Chien M et al (2006) Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2:113-121
64. Xiong B, Cheng Y, Ma L, Zhang C (2013) MiR-21 regulates biological behavior through the PTEN/PI-3K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 42:219-228. doi: 10.3892/ijo.2012.1707
65. Yantiss RK, Goodarzi M, Zhou XK et al (2009) Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 33:572-582. doi: 10.1097/PAS.0b013e31818afd6b
66. Yu Y, Sarkar FH, Majumdar APN (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 6:180-186
67. Zhang J, Guo H, Zhang H et al (2011) Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 117:86-95. doi: 10.1002/cncr.25522
68. Zhang G, Xia S, Tian H et al (2012) Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol Northwood Lond Engl 29:3108-3112. doi: 10.1007/s12032-012-0233-9
69. Zhong M, Bian Z, Wu Z (2013) miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem 31:209-218. doi: 10.1159/000343362
70. Zhu H, Dougherty U, Robinson V et al (2011) EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res Mcr 9:960-975. doi: 10.1158/1541-7786.MCR-10-0531